Secreted phospholipase A2 type IIA (sPLA2-IIA) activates integrins in an allosteric manner

13Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Secreted phospholipase A2 type IIA (sPLA2-IIA) is a well-established pro-inflammatory protein and has been a major target for drug discovery. However, the mechanism of its signaling action has not been fully understood. We previously found that sPLA2-IIA binds to integrins αvβ3 and α4β1 in human and that this interaction plays a role in sPLA2-IIA’s signaling action. Our recent studies found that sPLA2-IIA activates integrins in an allosteric manner through direct binding to a newly identified binding site of integrins (site 2), which is distinct from the classical RGD-binding site (site 1). The sPLA2-IIA-induced integrin activation may be related to the signaling action of sPLA2-IIA. Since sPLA2-IIA is present in normal human tears in addition to rheumatoid synovial fluid at high concentrations the sPLA2-IIA-mediated integrin activation on leukocytes may be involved in immune responses in normal and pathological conditions.

Cite

CITATION STYLE

APA

Takada, Y., & Fujita, M. (2017). Secreted phospholipase A2 type IIA (sPLA2-IIA) activates integrins in an allosteric manner. In Advances in Experimental Medicine and Biology (Vol. 925, pp. 103–115). Springer New York LLC. https://doi.org/10.1007/5584_2016_95

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free